IFNG and breast cancer: Importantly, SATB1565–574 peptide-specific T cells recognized and killed HLA-A*02+ SATB1-expressing Jeko-1, Skov-1 cells as well as IFN-γ-treated breast cancer cell lines (CAMA-1 and MDA-MB-231), suggesting this peptide is naturally processed by cancer cells.